{"title":"利用临床声明数据库评价β -微球蛋白吸附治疗透析相关淀粉样变性的疗效。","authors":"Chikao Onogi, Akihito Tanaka, Kazuhiro Furuhashi, Shoichi Maruyama","doi":"10.1159/000547964","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Dialysis-related amyloidosis (DRA) is a refractory complication of long-term dialysis caused by β2-microglobulin (β2MG) deposition. While β2MG adsorption columns remove β2MG, their impact on preventing re-surgery remains unclear.</p><p><strong>Methods: </strong>This a noninterventional, population-based cohort study used a large-scale medical claims database. This study included patients with chronic kidney disease undergoing maintenance hemodialysis (HD) and diagnosed with DRA. The exposure group received β2MG adsorption column therapy, while the control group was divided into online hemodiafiltration (OHDF) and HD subgroups. The primary endpoint was carpal tunnel or trigger finger release.</p><p><strong>Results: </strong>Among 3,946 eligible patients, 212 patients in the β2MG adsorption column group, 139 in the OHDF group, and 237 in the HD group were included; the primary endpoint occurred in 28 (13.2%), 21 (15.1%), and 37 (15.6%) patients, respectively. Although there was a trend toward a lower incidence in the β2MG adsorption column group, no significant difference was observed (p = 0.43). The adjusted hazard ratio for the β2MG adsorption column group (HD group as reference) tended to be low (0.68, 95% CI: 0.41-1.13), but this difference was not significant.</p><p><strong>Conclusions: </strong>Although there was no statistically significant difference, the findings suggest that the β2MG adsorption column may help slow DRA progression.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-8"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the Therapeutic Effects of Beta2-Microglobulin Adsorption on Dialysis-Related Amyloidosis Using a Clinical Claims Database.\",\"authors\":\"Chikao Onogi, Akihito Tanaka, Kazuhiro Furuhashi, Shoichi Maruyama\",\"doi\":\"10.1159/000547964\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Dialysis-related amyloidosis (DRA) is a refractory complication of long-term dialysis caused by β2-microglobulin (β2MG) deposition. While β2MG adsorption columns remove β2MG, their impact on preventing re-surgery remains unclear.</p><p><strong>Methods: </strong>This a noninterventional, population-based cohort study used a large-scale medical claims database. This study included patients with chronic kidney disease undergoing maintenance hemodialysis (HD) and diagnosed with DRA. The exposure group received β2MG adsorption column therapy, while the control group was divided into online hemodiafiltration (OHDF) and HD subgroups. The primary endpoint was carpal tunnel or trigger finger release.</p><p><strong>Results: </strong>Among 3,946 eligible patients, 212 patients in the β2MG adsorption column group, 139 in the OHDF group, and 237 in the HD group were included; the primary endpoint occurred in 28 (13.2%), 21 (15.1%), and 37 (15.6%) patients, respectively. Although there was a trend toward a lower incidence in the β2MG adsorption column group, no significant difference was observed (p = 0.43). The adjusted hazard ratio for the β2MG adsorption column group (HD group as reference) tended to be low (0.68, 95% CI: 0.41-1.13), but this difference was not significant.</p><p><strong>Conclusions: </strong>Although there was no statistically significant difference, the findings suggest that the β2MG adsorption column may help slow DRA progression.</p>\",\"PeriodicalId\":8953,\"journal\":{\"name\":\"Blood Purification\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Purification\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000547964\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Purification","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547964","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Evaluation of the Therapeutic Effects of Beta2-Microglobulin Adsorption on Dialysis-Related Amyloidosis Using a Clinical Claims Database.
Introduction: Dialysis-related amyloidosis (DRA) is a refractory complication of long-term dialysis caused by β2-microglobulin (β2MG) deposition. While β2MG adsorption columns remove β2MG, their impact on preventing re-surgery remains unclear.
Methods: This a noninterventional, population-based cohort study used a large-scale medical claims database. This study included patients with chronic kidney disease undergoing maintenance hemodialysis (HD) and diagnosed with DRA. The exposure group received β2MG adsorption column therapy, while the control group was divided into online hemodiafiltration (OHDF) and HD subgroups. The primary endpoint was carpal tunnel or trigger finger release.
Results: Among 3,946 eligible patients, 212 patients in the β2MG adsorption column group, 139 in the OHDF group, and 237 in the HD group were included; the primary endpoint occurred in 28 (13.2%), 21 (15.1%), and 37 (15.6%) patients, respectively. Although there was a trend toward a lower incidence in the β2MG adsorption column group, no significant difference was observed (p = 0.43). The adjusted hazard ratio for the β2MG adsorption column group (HD group as reference) tended to be low (0.68, 95% CI: 0.41-1.13), but this difference was not significant.
Conclusions: Although there was no statistically significant difference, the findings suggest that the β2MG adsorption column may help slow DRA progression.
期刊介绍：
Practical information on hemodialysis, hemofiltration, peritoneal dialysis and apheresis is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also patient comfort and disease improvement through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, internists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative. ''Blood Purification'' also serves as a platform for multidisciplinary experiences involving nephrologists, cardiologists and critical care physicians in order to expand the level of interaction between different disciplines and specialities.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
